Compounds > 1-hexadecyl-2-acetyl-glycero-3-phosphocholine
Page last updated: 2024-09-02

1-hexadecyl-2-acetyl-glycero-3-phosphocholine and cinalukast

1-hexadecyl-2-acetyl-glycero-3-phosphocholine has been researched along with cinalukast in 1 studies

Compound Research Comparison

Studies
(1-hexadecyl-2-acetyl-glycero-3-phosphocholine)		Trials
(1-hexadecyl-2-acetyl-glycero-3-phosphocholine)		Recent Studies (post-2010)
(1-hexadecyl-2-acetyl-glycero-3-phosphocholine)		Studies
(cinalukast)		Trials
(cinalukast)		Recent Studies (post-2010) (cinalukast)
9,15618755225110

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (100.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Cashin, C; Newbold, P; O'Donnell, M; Renzetti, L; Simko, B; Tocker, J; Wasserman, MA; Welton, AF1

Other Studies

1 other study(ies) available for 1-hexadecyl-2-acetyl-glycero-3-phosphocholine and cinalukast

ArticleYear
Studies of the combination of Ro 24-5913, a peptidoleukotriene antagonist, and Ro 24-4736, a PAF antagonist, in guinea pig and rat models of lung inflammation.
    Annals of the New York Academy of Sciences, 1994, Nov-15, Volume: 744

    Topics: Animals; Bronchoconstriction; Guinea Pigs; Lung; Male; Phenanthridines; Platelet Activating Factor; Pneumonia; Rats; SRS-A; Thiazoles; Triazines

1994